Major Causes of Morbidity and Mortality in SLE
Patient EM

- EM, an 18-year-old Black female presents to the emergency department (ED) with acute onset of confusion and hallucinations
- Her parents report she has been complaining of “fatigue” for the past 6 months and has lost 5 pounds. An antinuclear antibody test (ANA) ordered by her primary physician last week was strongly positive
- Abnormal physical findings include a low-grade fever of 100 °F and several small oral ulcers
- Labs: strongly positive anti-dsDNA antibody, borderline anti-Sm and normal levels of C3 and C4
- EM develops disorganized thinking, lack of orientation, agitation, and delusions (consistent with acute confusional state). She is admitted to the hospital
Addressing EM’s symptoms involves:

- Exclusion of secondary causes of confusion (infectious, metabolic, drug-induced, vascular)
- Imaging and lumbar puncture to help to determine cause
- Measurement of antiphospholipid antibodies, which can, in some patients, alter the management plan

Patient is treated with steroids and hydroxychloroquine

Management with steroids/immunosuppression is complicated by an episode of *Escherichia coli* (*E. coli*) pyelonephritis in the hospital

When an 18-year-old is seen at the ED, the physician usually addresses the acute problem and the teenager goes back to normal life; however, EM’s journey is different

Introduction

• Major causes of morbidity in systemic lupus erythematosus (SLE)
  – Neuropsychiatric
  – Renal
  – Cardiovascular
  – Other (bone-related, malignancy, infections, hematologic)

• Mortality in SLE
Neuropsychiatric Lupus (NPSLE)

- 19 case definitions of neuropsychiatric manifestations
- Most commonly:
  - Cognitive dysfunction
  - Headache
  - Psychiatric disorders (anxiety, psychosis,* depression)
  - Seizures*
  - Stroke (may be associated with antiphospholipid antibodies)
  - Peripheral neuropathies

*Part of the classification criteria for SLE.

Epidemiology of NPSLE

• Cumulative incidence is ~30%–40%

• In early disease
  – ~20% of patients already have atrophy on brain MRI
  – ~10% have focal lesions

• Not all neuropsychiatric manifestations in lupus patients are directly attributable to lupus. Two thirds may be due to other causes
Correct Attribution of Neuropsychiatric Events Is Critical—Consider Other Causes

- Non-SLE disease-related etiologies of neuropsychiatric symptoms that should be considered
  - Infections
  - Medications and toxins
    - Prescription medications
    - Illicit drugs
    - Dietary supplements
    - Alternative and complementary therapies
  - Cardiovascular
    - Hypertension
    - Ischemic stroke
    - Hemorrhagic stroke
  - Other
Radiologic Findings (CT and MRI)

- Atrophy (most common)
- Vascular abnormalities
- Demyelination
- Inflammation

A. The initial MRI scan with fluid-attenuated inversion-recovery reveals multiple high-intensity areas in the deep white matter.

B. 4 months later, there is significant cerebral atrophy, characterized by a loss of brain volume, along with multiple high-intensity areas.

Vascular Lesions

• Vascular lesions include:
  – Hemorrhages
  – Ischemic stroke and microinfarcts
    ■ Associated with antiphospholipid antibodies
  – Vasculopathy with perivascular lymphocytic infiltrate and endothelial cell proliferation
  – Vasculitis (rare)

• Associated clinical syndromes
  – Acute – headache, stroke, and seizures
  – Chronic cognitive impairment due to recurrent microinfarcts
Injury to the Brain Parenchyma

• Diffuse central nervous system syndromes often wax and wane
  – Acute confusional state, psychosis, and mood disorders
  – Suggests temporary neuronal dysfunction

• Cerebrospinal fluid analysis may indicate local inflammation
  – Increased lymphocytes and proinflammatory cytokines
  – Elevated protein levels and autoantibodies

• Specific autoantibodies have been associated with neuronal toxicity
Parenchymal Brain Lesions Often Indicate Penetration of the Blood-Brain Barrier

The blood-brain barrier is controlled by tight junctions between endothelial cells.

- Altered endothelial cell function can destabilize the blood-brain barrier
  - Inflammatory mediators due to infection or flare
  - Hypertension
  - Smoking and other toxins
  - Stress

Cognitive Dysfunction Is Common in Lupus Patients

• Observed in 50%–80% of lupus patients

• Problems with:
  – Attention
  – Concentration
  – Memory
  – Word-finding

• Attribution of cognitive dysfunction to lupus is difficult

“I have to squeeze my brain really hard to get a thought out!”

Many Causes of Cognitive Dysfunction in Lupus

- Medications
- Metabolic dysfunction
- Strokes
- Thrombotic thrombocytopenic purpura
- Depression/anxiety
- Sleep disorders
- Neuronal toxicity (antibodies, cytokines)
- Vasculitis
- Antiphospholipid syndrome
Peripheral Nervous System Involvement

- Neuropathies (motor or autonomic) or myasthenia gravis-like syndrome
- SLE/myasthenia overlap is associated with antiacetylcholine receptor antibodies
- Circulating antibodies and inflammatory mediators have direct access to peripheral nerves
Transverse Myelitis

• Transverse myelitis is a rare, late manifestation of SLE but can occur at presentation

• Most patients, but not all, demonstrate a sensory level with spastic weakness and sphincter dysfunction
Transverse Myelitis

(a) Sagittal T2-weighted, gadolinium-enhanced MRI of the spine of a 38-year-old female SLE patient showing cord enlargement and hyperintense signal in the C2, C4–C6, and C7–T1 spinal cord (arrows), consistent with longitudinal spinal myelitis.

(b) Posttreatment MRI of the spine demonstrates complete resolution of the T2 hyperintense signal.

Neuropsychiatric Lupus—Identifying the Cause Will Determine Treatment

• NPSLE manifestations may occur during periods of disease quiescence in other organs
• Correct ascertainment and attribution is critical
  – For example, an ischemic stroke due to long-standing diabetes and hypertension should not be treated with immunosuppression
• Immunosuppression for inflammatory manifestations
• Traditional drugs for headache, seizures, stroke, and mood disorders
• Stress management and psychotherapy
Conclusions—Neuropsychiatric Lupus

- The most common causes of neuropsychiatric involvement are non-lupus related. Rule out other causes first
- NPSLE encompasses a broad range of clinical presentations and pathologies
  - Vascular lesions can cause both acute focal and chronic diffuse impairment
  - Autoantibodies and other proinflammatory molecules that cross the blood-brain barrier may have direct effects on neurons, resulting in altered cellular function or death
  - Peripheral nerves are exposed to the circulation
- Correct diagnosis is critically important to ensure that appropriate therapy is used
Patient EM

• Resolution of symptoms and decrease in anti-dsDNA antibodies over 6–8 weeks is followed by steroid taper over the next 6 months. She was maintained on hydroxychloroquine and followed every 3 months but is lost to follow-up after 2 years

• 3 years later, at age 23, she presents with fever and joint pains after returning from a trip to Jamaica. In the last 3 days, she has noticed mild swelling of both ankles

• Anti-dsDNA antibodies have significantly increased since her last visit. Both C3 and C4 are decreased below normal

• Urinalysis reveals 300 mg/dL proteinuria and 5 WBC/hpf. Her serum creatinine is normal
Epidemiology of Lupus Nephritis

- Prevalence: 30%–65% in adults and 80% in children
- 10% annual incidence in 1 large cohort
- More frequent and severe in children, Blacks, Hispanics, and males
- Strong predictor of morbidity and mortality
Nephritis Is Induced by Renal Deposition of Antibodies

Anatomy of the glomerulus, consisting of a tuft of capillary loops fed by the afferent arteriole. The tuft is held together by the mesangium. The enlarged capillary loop shows the components of the glomerular filtration barrier. The barrier is formed by the glycocalyx, fenestrated endothelial cells (End), glomerular basement membrane (GBM), podocyte foot processes (Pod and FP), and slit diaphragm (SD). The podocyte layer is contiguous with the parietal epithelial layer (PEp), which is surrounded by the Bowman capsule. Immune deposits may be found on either side of the GBM (SubEnd or SubEp) or in the mesangium (Mes).

Tubular and vascular deposits may also occur.
Immune Complex Deposits

Subepithelial deposits found in membranous disease

Subendothelial deposits found in proliferative disease

Image courtesy of the Rheumatology Image Bank
Clinical Diagnosis of SLE Nephritis

• Increase in proteinuria is most common
  – Measured by spot protein:creatinine ratio >0.5 or 24-hour collection >500 mg/24 hours
  – The absolute increase in proteinuria that defines a nephritis flare is arbitrary

• Microscopic abnormalities on urinalysis
  – White cells or red blood cells >5 cells/hpf in the absence of infection or other causes
  – Cellular casts (white cell or red cell)
  – White cells and red blood cells are seen more frequently than casts

Lupus Renal Pathology

- Renal biopsy is used routinely to evaluate disease type and severity and to direct management.
- All patients with clinical evidence of active lupus nephritis, and previously untreated, should have a kidney biopsy (unless strongly contraindicated).
- Treatment is based on biopsy results:
  - Proliferative disease is treated more aggressively than mesangial and membranous disease because it progresses more rapidly and is more likely to cause chronic damage.
Renal Pathology—International Society of Nephrology Scores*

• Class I – Minimal mesangial glomerulonephritis – deposits but normal light microscopy

• Class II – Mesangial proliferative glomerulonephritis

• Class III – Focal glomerulonephritis involving <50% of glomeruli

*2002 International Society of Nephrology/Renal Pathology Society (ISN/RPS).
• Class IV – Diffuse glomerulonephritis involving ≥50% glomeruli

• Class V – Membranous glomerulonephritis

• Class VI – Advanced sclerosing lupus nephritis >90% sclerotic glomeruli (kidney biopsy stained with a combination of PAS and trimchrome stain)

*2002 International Society of Nephrology/Renal Pathology Society (ISN/RPS).

# Classes of Lupus Nephritis

<table>
<thead>
<tr>
<th>Class of Lupus Nephritis*</th>
<th>Typical Laboratory/Clinical Findings</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>I Minimal mesangial</td>
<td></td>
<td>Good, no treatment</td>
</tr>
<tr>
<td>II Mesangial proliferative</td>
<td></td>
<td>Good, no treatment</td>
</tr>
<tr>
<td>III Focal proliferative</td>
<td>Hypertension, proteinuria, active urine sediment, +dsDNA, low C3/C4, rising Cr</td>
<td>Severe, aggressively treat</td>
</tr>
<tr>
<td>IV Diffuse proliferative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V Membranous</td>
<td>Heavy proteinuria, bland sediment</td>
<td>Intermediate, treat</td>
</tr>
<tr>
<td>VI Advanced sclerosing</td>
<td></td>
<td>End-stage renal disease</td>
</tr>
</tbody>
</table>

*Patients can have mixed classes; for example, proliferative and membranous lupus nephritis.

Progression to End-Stage Renal Disease

- 10%–30% progress within 15 years
- Rate of end-stage renal disease (ESRD) in the United States due to SLE appears to be increasing (especially in younger age groups, Blacks, and the Southeast)
- Mortality rates from ESRD are stable
- 5-year mortality of children with ESRD is 22%
- Many disparities exist in access to treatment and transplantation

Video of Dr. Bevra Hahn and Liz Shaw Stabler (Patient)

University of California Los Angeles, School of Medicine
Treatment of Proliferative Lupus Nephritis Classes III/IV

• **Induction** – intensive immunosuppression to reduce inflammation by controlling immunologic causes of injury

• Immunosuppression with either cyclophosphamide or high-dose mycophenolate mofetil and steroids is superior to steroids alone

• Mycophenolate mofetil is preferred in patients who desire to preserve fertility

• The ACR guidelines recommend mycophenolate mofetil in Blacks over cyclophosphamide as the drug of first choice

• The ACR guidelines recommend a 3-day IV pulse of steroid as part of induction of therapy

• Induction therapy is recommended for 6 months
Treatment of Proliferative Lupus Nephritis Classes III/IV (cont.)

- **Maintenance** – longer period of less-intensive therapy to prevent flare
  - Mycophenolate mofetil is the current standard of care; azathioprine can be used as an alternative
  - Length of time needed is not well defined (>3 years)

- **Adjunct therapy**
  - Hydroxychloroquine
  - Angiotensin-converting enzyme (ACE) inhibitors
  - Control blood pressure to goal of ≤130/80 mm

Pure Membranous Nephritis

- 50% of patients are serologically inactive at presentation
- Supportive treatment
  - ACE inhibitors can decrease proteinuria
  - Hypercoagulability requires treatment on an individualized basis
  - Rigorous control of blood pressure
  - Aggressive treatment of dyslipidemia
- Immunosuppression (mycophenolate mofetil) and steroids (prednisone) are used for patients with nephrotic range proteinuria or progressive disease
- When patients present with a mixed-type pathological process, the treatment is tailored to the more aggressive type of process (Class III or IV–V)

Limitations of Current Therapies

• **Toxicity**
  – Infections (especially in leukopenic patients)
  – Infertility (cyclophosphamide)
  – Malignancy – bladder (cyclophosphamide), cervical dysplasia
  – Multiple toxicities of long-term or high-dose steroid use

• **Efficacy**
  – Remission rates ~50%
  – Relapse rates 30%–50% by 2–3 years
  – Rates of ESRD due to SLE are increasing in the United States, especially in Blacks

Risks for Developing End-Stage Renal Disease

• Demographics
  – Younger age or male gender
  – Poverty

• Clinical features
  – Hypertension
  – Autoantibodies and low complement
  – Abnormal renal function at presentation

• Delay in treatment

• Failure to respond to treatment, or flare after remission

Monitoring to Minimize Future Complications

- Address factors that contribute to a poor outcome
  - Treat hypertension aggressively
  - Consider the use of ACE inhibitors and angiotensin II receptor blockers (ARBs)
  - Address psychosocial factors
- Manage long-term atherosclerosis risks
- Prevent adverse effects of medications
  - Consider prophylaxis for infections
  - Ensure yearly Pap test and other cancer screening as clinically indicated
  - For patients taking cyclophosphamide, interventions to prevent infertility and bladder toxicity should be considered
  - Manage bone health
Conclusions—SLE Nephritis

- Nephritis is a common manifestation of SLE
- Proliferative nephritis is the most common form
- Treatment of proliferative disease involves induction of remission followed by maintenance immunosuppression
- Membranous nephritis is not a benign condition, and treatment is indicated in patients with significant proteinuria
- Current therapies are toxic and insufficiently effective, and ESRD still ensues in 10%–30% of patients
Patient EM

• EM responds to high-dose mycophenolate mofetil and prednisone. She is maintained on low-dose mycophenolate mofetil and 5 mg prednisone daily for 2 years, and is then switched to azathioprine as she wants to get pregnant

• She gains 50 pounds over this time, which she is unable to lose

• 2 subsequent arthritic flares are treated with moderate-dose prednisone. She is maintained on hydroxychloroquine and prednisone 7.5 mg/day

• She requires an ACE inhibitor for mild hypertension and at age 36 develops type 2 diabetes. Her HbA1C is always above normal

• At age 43 she presents to the ED with central chest pain on exertion and is found to have an inferior myocardial infarction
Premature Atherosclerosis and SLE

- A leading cause of mortality in lupus patients
- 5-fold increased risk of coronary artery disease, especially in younger patients
  - Overall, 10-year risk for a coronary event or stroke is 7.5- to 17-fold increased
  - Rate of myocardial infarction is 50-fold higher in 35- to 44-year-old age group
  - 1st cardiac event occurs at ≤55 years old in more than 2/3 patients
- Pathology and clinical presentation is similar to that of general population but outcomes are worse
- Women in general can present atypically

Causes of Cardiovascular Mortality in Lupus

Traditional Cardiac Risk Factors:
- Age
- Smoking
- Hypertension
- Sedentary lifestyle
- Metabolic syndrome
- Diabetes
- Gender
- Obesity
- Dyslipidemia
- Family history
- Insulin resistance

Increased CVD Morbidity

Increased CVD Mortality

Disease-Related Factors and Treatment

Adapted from: Symmons DP, Gabriel SE. Nat Rev Rheumatol. 2011;7(7):399-408.
Atherosclerosis Evaluation in Lupus

- EKG and stress test when indicated based on clinical history and exam
- Obtain lipid profiles and manage elevated cholesterol
- Aggressive assessment and control of modifiable cardiovascular risk factors, including obesity, smoking, and high blood pressure

Other Morbidities to Consider

- Bone-related
- Malignancy
- Infections
- Hematologic
Bone Health in Women With Lupus

• Osteonecrosis, a rare condition in healthy individuals, is a major cause of morbidity in some lupus patients. Patients with this condition often require surgical intervention.

• Women with lupus are nearly 5 times more likely to experience a fracture from osteoporosis than those without lupus.

• Likely contributors to this increased risk include:
  – Glucocorticoid use
  – Sun avoidance (contributing to vitamin D deficiency)
  – Disease-related mechanisms

Bone Health in Women With Lupus (cont.)

- Prevention and management of bone loss is critical to prevent fractures
  - Ensure adequate calcium and vitamin D intake
  - Encourage regular exercise, particularly weight-bearing
  - Advise avoidance of smoking or heavy drinking, which can worsen bone loss
  - Assess risk with bone densitometry (DXA) and/or fracture risk assessment tools (FRAX) according to National Osteoporosis Foundation guidelines
  - Treat with medications, such as bisphosphonates, when indicated and appropriate

Increased Malignancy Risk With SLE

Cancers observed and expected, with standardized incidence ratio (SIR) and 95% confidence intervals (95% CI)*

<table>
<thead>
<tr>
<th>Malignancy</th>
<th>Observed</th>
<th>Expected</th>
<th>SIR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cancers</td>
<td>431</td>
<td>373.3</td>
<td>1.15</td>
<td>1.05–1.27</td>
</tr>
<tr>
<td><strong>Hematologic cancers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All‡</td>
<td>67</td>
<td>24.4</td>
<td>2.75</td>
<td>2.13–3.49</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>42</td>
<td>11.5</td>
<td>3.64</td>
<td>2.63–4.93</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>5</td>
<td>2.1</td>
<td>2.36</td>
<td>0.75–5.51</td>
</tr>
<tr>
<td>Leukemia</td>
<td>7</td>
<td>3.7</td>
<td>1.89</td>
<td>0.76–3.88</td>
</tr>
<tr>
<td><strong>Reproductive cancers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>73</td>
<td>96.1</td>
<td>0.76</td>
<td>0.60–0.95</td>
</tr>
<tr>
<td>Ovary</td>
<td>9</td>
<td>14.5</td>
<td>0.62</td>
<td>0.28–1.18</td>
</tr>
<tr>
<td>Cervix §</td>
<td>14</td>
<td>11.1</td>
<td>1.26</td>
<td>0.69–2.11</td>
</tr>
<tr>
<td>Vagina</td>
<td>2</td>
<td>0.4</td>
<td>4.91</td>
<td>0.49–17.69</td>
</tr>
<tr>
<td>Vulva</td>
<td>2</td>
<td>1.3</td>
<td>1.60</td>
<td>0.16–5.76</td>
</tr>
<tr>
<td>Uterus</td>
<td>6</td>
<td>16.9</td>
<td>0.36</td>
<td>0.13–0.78</td>
</tr>
<tr>
<td><strong>Other cancers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>62</td>
<td>45.3</td>
<td>1.37</td>
<td>1.05–1.76</td>
</tr>
<tr>
<td>Hepatobiliary</td>
<td>10</td>
<td>3.8</td>
<td>2.60</td>
<td>1.25–4.78</td>
</tr>
<tr>
<td>Colorectal</td>
<td>40</td>
<td>39.5</td>
<td>1.01</td>
<td>0.72–1.38</td>
</tr>
<tr>
<td>Pancreas, gastric, colorectal, thyroid, bladder, prostate, melanoma—low #, nonsignificant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Data shown are for 23 participating sites in North America, Europe, Iceland, and Asia. The total number of patients was 9547 (76,948 patient-years). The calendar period was 1958–2000. In addition to the categories presented, the total included the following cancers: 21 nonmelanoma skin, 18 primary unknown, 15 head and neck, 12 kidney, 7 central nervous system, 5 esophagus, 5 connective tissue, 3 larynx or mediastinum, 2 small intestine, 2 other female genitourinary, 1 adrenal gland. ‡Determined using the Poisson distribution. §Includes 7 multiple myeloma and 6 lymphoid malignancies not otherwise specified. | Includes invasive cancers; the only cancer registry data that include both invasive and in situ cervical neoplasms are data from the Saskatchewan Cancer Centre.
Infections and SLE

• Infections are a significant cause of hospitalizations and death

• Risk for infection is increased by:
  – Active disease
  – Immunosuppressive therapies
  – Leukopenia/lymphopenia
  – Low complement
Infections and SLE (cont.)

• Organisms
  – Bacterial (respiratory, urinary tract, and skin)
  – Viruses (herpes zoster, human papillomavirus)
  – Opportunistic (pneumocystis pneumonia, fungi)

• Opportunities for prevention
  – Vaccinations (inactivated influenza, pneumococcal, no live vaccines)
  – Screening for tuberculosis, hepatitis
  – Pneumocystis pneumonia prophylaxis for patients on more intensive immunosuppressive therapies
Hematologic Manifestations in Lupus—Peripheral Blood Cytopenias

• Any or all of the major lineages can be affected
  – Anemia
  – Leukopenia
    ▪ Neutropenia
    ▪ Lymphopenia
  – Thrombocytopenia

• Treatment depends upon identifying cause and assessing severity
Hematologic Manifestations in Lupus—Anemia

• Anemia is very common in lupus and often multifactorial
  – 25% mild (hematocrit 30%–35%)
  – 8% moderate (hematocrit 25%–29%)
  – 4% severe (hematocrit <25%)
    (cause not attributed)
• Most common causes
  – Anemia of chronic inflammatory disease
  – Anemia associated with renal disease (low erythropoietin)
  – Iron deficiency

Hematologic Manifestations in Lupus—Anemia (cont.)

- Hemolytic anemia (an ACR classification criteria)
  - Relatively rare, ranging from 5%–13%
  - Requires evidence of hemolysis (low haptoglobin and increased reticulocytes)
  - Coombs positivity (antibodies to red blood cells) alone much more common, as high as 40%
Hematologic Manifestations in Lupus—
Leukopenia and Lymphopenia

• Leukopenia
  – Defined as <4000 cells/µL
  – Usually an element of neutropenia
  – Prevalence of up to 50% sometime during course

• Lymphopenia
  – Defined as <1500 cells/µL
  – May be present in absence of leukopenia
  – Prevalence of up to 60%–70% sometime during course

Hematologic Manifestations in Lupus—Thrombocytopenia

- Defined as <100,000 platelets/µL
- Seen in 10%–25% of patients but severe (<50,000) less than 10%
- Causes
  - From lupus
    - Antiplatelet antibodies
    - Antiphospholipid antibodies
    - Thrombotic thrombocytopenic purpura/microangiopathic hemolytic anemia
  - From complications
    - Drug-induced bone marrow suppression
    - Infection

EM—What Could We Have Done Better?

• Education and attention to psychosocial factors
  – Advise sun protection: year-round use of SPF-45 or higher, clothing that is UV impenetrable and avoidance of UV exposure when possible
  – Encourage weight loss and exercise
  – Encourage compliance with clinic visits and medications
• Keep vaccinations up to date
• Monitor for early detection of flares
• Minimize steroid use
• Treat cardiac risk factors aggressively
• Monitor bone health
Reducing Adverse Events in Lupus

• Management of risks
  – Cardiovascular disease
  – Infection
  – Fracture
  – Cancer

• Hydroxychloroquine used as a background therapy
  – Reduce mortality
  – Decrease incidence of diabetes
  – Antithrombotic effects
  – Favorable lipid effects

Mortality Rate in SLE Is 2–3 Times Higher Than General Population

- Death rates have decreased by 60% in the United States since the 1970s, especially for infections and renal disease
- Risks of death increased in females, Blacks, and younger-onset patients
- Most common causes of death in SLE patients in the United States
  - Heart disease and stroke (1.7 x general population)
  - Hematologic malignancies and lung cancer (2.1 x general population)
  - Infections (5 x general population; also a common cause of hospitalization)
  - Renal disease (7.9 x general population)

Conclusions—Mortality and Morbidity in SLE

- Mortality and morbidity in SLE involves:
  - Active disease
  - Infectious consequences of chronic immunosuppressive therapy
  - Medication toxicities
  - Long-term sequelae of inflammation

- Each of these needs to be addressed proactively to achieve optimal long-term outcomes for individual patients
Bibliography
Slide 3 Reference

Slide 5 Reference

Slide 6 References


Slide 8 Reference

Slide 11 Reference

Slide 12 Reference
Slide 15 References


Slide 16 Reference

Slide 20 References


Slide 20 References (cont.)


Slide 21 Reference

Slide 23 Reference

Slide 26 Reference

Slide 27 References


**Slide 28 References**


**Slide 31 Reference**

**Slide 32 Reference**

**Slide 33 Reference**

**Slide 34 Reference**
Slide 35 Reference

Slide 39 References


Slide 40 Reference
Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7(7):399-408.

Slide 41 Reference

Slide 43 References


Slide 44 References


Slide 45 Reference

Slide 46 References


Slide 49 References


Slide 50 References


Slide 51 Reference

Slide 52 Reference

Slide 54 References

Slide 55 Reference